BIO 023

Drug Profile

BIO 023

Alternative Names: BIO023

Latest Information Update: 31 Mar 2011

Price : $50

At a glance

  • Originator Gardant Pharmaceuticals
  • Class
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Psoriasis

Most Recent Events

  • 31 Mar 2011 Discontinued - Phase-I for Psoriasis in USA (Injection)
  • 04 Jan 2007 Gardant Pharmaceuticals has been acquired by Switch Pharma
  • 22 Oct 2005 Phase-I clinical trials in Psoriasis in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top